ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Dec 15, 2017
Stop Using the Darn PE Ratio For Goodness Sake!
President of Investment Research Brian Nelson talks about his views with respect to backtests versus walk-forward tests, and explains why the PE ratio is doomed as a value tool. It's all psychological. Running Time: ~12 minutes.
Dec 14, 2017
Video: What Cash Flow Are You Talking About?
President of Investment Research Brian Nelson reviews important topics from the first six episodes of "Off the Cuff," and goes into great detail about all the intricacies of "cash flow" from traditional free cash flow to enterprise free cash flow valuation. You know you want to watch. Running Time: ~14 minutes.
Dec 14, 2017
Comment: Verint's Traditional Free Cash Flow
Image shown: Page 1 of 16, Valuentum's 16-page stock report on Verint (VRNT). Verint is free cash flow positive, implying that non-GAAP earnings adjustments are of high quality.
Dec 13, 2017
Nelson Answers Questions! Valu + entum
President of Investment Research Brian Nelson answers questions about the stock market and investing. Keep the emails and comments coming! Running time: ~10 minutes.
Dec 12, 2017
CVS Health at the Crossroads, Too Much Debt
Image Source: CVS Health. We have been disappointed with the lack progress displayed by CVS Health thus far in 2017. We knew the business was entering into an earnings trough as a result of key contract losses, but recent events have unfolded that, in our view, have lessened the attractiveness of its business model, to a meaningful degree. Let’s talk more about what’s happening at CVS Health, the changing PBM market, Amazon’s threat, and too much leverage. We’re not overreacting, but we’re not happy either.
Dec 11, 2017
Video: Nelson's Active Management Theorem, Poker and "High Society," Inertia and the Value-Growth Conundrum
President of Investment Research Brian Nelson details his simple new theorem of the stock market that may change everything you believe. Nelson explains using poker as an example, and he goes on to caution about the concept of inertia, and how investing has somehow transformed into a "game" -- if investors truly believe there are 'value' and 'growth' stocks. A must-watch intrigue. Running time: ~11 minutes.
Dec 11, 2017
Omega Healthcare and Holly Energy Partners: Case Studies in REIT and MLP Income Evaluation
Image shown: The performance of the Vanguard REIT ETF (VNQ) during the Financial Crisis in 2007-2009. An assessment of a REIT’s or MLP’s dividend/distribution strength not only should reflect firm-specific fundamentals, but also external market conditions, which are paramount to the sustainability of most any REIT’s or MLP’s payout. Let’s remind readers of this important dynamic, which is captured via the two different Dividend Cushion ratios, and walk through what goes into the analysis we pursue when making a change with respect to our assessment of a company’s dividend health or safety.
Dec 10, 2017
Video: Indexing/Quant Bubble, Pitfalls of Backward Multiple Analysis, and Thoughts on the CAPE Ratio
President of Investment Research Brian Nelson talks about what causes a stock pricing bubble, notes how the "price setters" are disappearing in today's market, explains the pitfalls of backward-looking multiple analysis, and shares his thoughts on the CAPE (cyclically-adjusted price-to-earnings) ratio. Running time: ~11 minutes
Dec 10, 2017
Follow Up on Loxo Oncology, Clovis Oncology, and Nevro
We like to write about a wide range of ideas in the financial markets, even if such ideas may be well beyond the high end of our own risk spectrum. Our writings on the smaller, high-growth (and riskier) ideas in healthcare/biotech, for example, remain an attempt to draw attention to some of the fantastic innovation helping to reshape treatment paradigms. Let’s follow up on some of the high-risk companies in the healthcare/biotech arena that we previously highlighted.
Dec 10, 2017
Global Blood Therapeutics Follow Up
Image Source: Biotechnology Innovation Organization. In this piece, let’s discuss the recent positive events that have unfolded for Global Blood Therapeutics.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.